[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Stratpharma AG\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":117},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,74,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100628914","prevention-of-stretch-marks-in-expectant-mothers-100628914",false,"NCT07467837","Prevention of Stretch Marks in Expectant Mothers","Prevention (Reduction of Incidence) of Stretch Marks in Expectant Mothers","PRIME","Inclusion Criteria:\n\n* Pregnant women at any gestational age.\n* Participants who are in good health, including those that are carrying multiples, who are 18 years of age or older.\n* Confirmed absence of pre-existing stretch marks on the abdomen.\n* Agree to apply Stratamark according to the prescribed protocol for the duration of the study.\n* Ability to complete remote online surveys via an electronic device.\n* Provide signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Visible stretch marks on the abdomen prior to enrollment.\n* Pre-existing skin conditions (e.g., eczema, psoriasis), on the abdomen that could interfere with product application or assessment of stretch marks.\n* Known hypersensitivity or allergy to any of the ingredients in Stratamark.\n* Use of other topical treatments on the abdomen, including but not limited to oils, or creams targeting stretch mark prevention.\n* Participants unable to give informed consent, or unable to have written consent provided on their behalf.\n* Participants who cannot administer the treatment or have the treatments administered as per the directions for use.","FEMALE","18 Years",{"count":20,"type":21},10000,"ESTIMATED","30 Weeks","OBSERVATIONAL","PRIME Mothers is a national observational trial designed to evaluate patient outcomes with Stratamark® for the prevention of stretch marks during pregnancy and the postpartum period. The study is designed to fit seamlessly into routine clinical practice, with digital follow-up and home resupply, minimising clinic involvement.",[26,27],"Pregnant Women","Stretch Mark",[29,30,31],"Stratamark","expectant mothers","prevention of stretch marks","RECRUITING","2026-03-11",{"date":35,"type":36},"2026-03-12","ACTUAL",{"date":38,"type":36},"2026-02-24",{"date":40,"type":21},"2027-02",{"name":42,"class":43},"Stratpharma AG","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100512487","valor-vaginal-atrophy--long-term-observation-of-recovery-100512487","NCT05953090","VALOR: Vaginal Atrophy & Long-term Observation of Recovery","VALOR","Inclusion Criteria:\n\n* Diagnosed atrophic vaginitis, lichen sclerosus, lichen simplex chronicus or lichen planus\n* Continuous vulvovaginal symptoms\n* Access to smartphone and tablet, laptop or computer\n* Access to a valid email address\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Patient unable to apply topical device\n* Allergy or intolerance to ingredients or excipients of the formulation of studied products\n* Systemic hormonal therapy started less than 30 days before baseline\n* Systemic corticosteroids ongoing treatment or used within the last 30 days before baseline\n* Ongoing topical HRT or corticosteroid treatment for the indication under investigation\n* Topical HRT or corticosteroid treatment used for the indication under investigation within the last 30 days before baseline",{"count":53,"type":21},2000,"INTERVENTIONAL",[56],"NA","Vulvovaginal skin conditions, namely vaginal atrophy, lichen sclerosus, lichen simplex chronicus and lichen planus affecting the female adult population will be treated with a novel gel dressing to test the short- and long-term safety and efficacy of the device.",[59,60,61,62,63,64],"Atrophic Vaginitis","Vaginal Atrophy","Genitourinary Syndrome of Menopause","Lichen Sclerosus of Vulva","Lichen Planus of Vulva","Lichen Simplex of Vulva (Disorder)","2026-02-19",{"date":67,"type":36},"2026-02-20",{"date":69,"type":36},"2023-10-30",{"date":71,"type":21},"2028-12",{"name":42,"class":43},14,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":54,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100490959","silicone-gel-vs-estrogen-vaginal-cream-for-the-management-of-genitourinary-syndrome-of-menopause-100490959","NCT05672901","Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause","Comparison of a Novel Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause: a Non-inferiority Trial","VITAL-E","Inclusion Criteria:\n\n* Able to provide informed consent\n* Confirmed postmenopausal age\n* Diagnosed genitourinary syndrome of menopause\n* Access to a smartphone, tablet or computer, and to a functional email address.\n\nExclusion Criteria:\n\n* Contraindication for the use of estrogen therapy\n* Unable to provide informed consent\n* Patient unable to apply topical device\n* Allergy or intolerance to ingredients or excipients of the formulation of studied products",{"count":83,"type":21},100,[56],"The goal of this randomized controlled trial is to test the efficacy of StrataMGT in the management of Genitourinary Syndrome of Menopause (GSM) compared to estrogen therapy. The main question it aims to answer is:\n\n\\- Will StrataMGT be non-inferior regarding patient quality of life compared to standard of care?\n\nParticipants will use either StrataMGT or estrogen vaginal cream to treat GSM for 3 consecutive months. After the baseline assessment, participants will be assessed monthly for quality of life, clinical signs, symptoms, pathology and adverse reactions.",[61],{"date":67,"type":36},{"date":89,"type":36},"2023-04-04",{"date":91,"type":21},"2026-09",{"name":42,"class":43},3,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":54,"phases":104,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":44},"100619566","phase-4-assist-vla-assessment-of-symptom-specific-improvement-in-diagnosed-vaginal-atrophy-following-laser-therapy-100619566","NCT07346287","ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy","Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy (ASSIST-VLA)","ASSIST-VLA","Inclusion Criteria:\n\n* Diagnosed vaginal atrophy\n* Access to smartphone and tablet, laptop or computer\n* Access to a valid email address\n* Previously completed laser therapy session schedule\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Patient unable to apply topical device\n* Allergy or intolerance to ingredients or excipients of the formulation of studied products\n* Systemic hormonal or steroidal therapy started less than 30 days before baseline ( = not yet on a stable regimen)",{"count":103,"type":21},10,[105],"PHASE4","Vaginal atrophy patients receiving vaginal laser therapy will be treated with daily 7-0940® following a laser session to evaluate the safety and efficacy of the product as an adjunct treatment. Clinical outcomes will be assessed using validated investigator- and patient-reported measures, with safety and symptom progression monitored throughout the study.",[60,59,108],"Genitourinary Syndrome of Menopause (GSM)","2026-01-15",{"date":111,"type":36},"2026-01-16",{"date":113,"type":36},"2025-08-13",{"date":115,"type":21},"2026-04",{"name":42,"class":43},""]